In the service of Health

 
2015 is the 20th anniversary of MédiS laboratories.

2015 is the 20th anniversary of MédiS laboratories.

"It‘s been 20 years ago when MédiS was just an ambition with vague outline, A lined intuition of a profound conviction of success of the dream of my life..." Lassaad BOUJBEL | Founder and Pharmacist MédiS CEO

Lire la suite

Quality Control Laboratory

Quality Control Laboratory

The quality control department, within MédiS Laboratories, is one of the complex systems of quality evaluation in its widest sense, ensuring diverse activities of control and expertise…

Lire la suite

News

02.03.2015

Médis Laboratories Launches 1st recombinant human erythropoietin produced in Tunisia

After granting the Marketing Authorization of THE FIRST Human Recombinant alpha Erythropoietin (EPO), MédiS becomes the FIRST Tunisian pharmaceutical company to produce and market its biosimilar EPO commercially appointed as EPOMAX®.

Erythropoietin (EPO) is an hormone which acts as a growth factor for the red cell precursors in the bone marrow. Secretion results in an increase of red blood cells in the blood. It is produced mainly by the kidney (90%) and decreases with the progression of renal insufficiency. It is intended primarily for hemodialysis patients with blood anemia.

Access to this treatment will affect more than 8,000 patients treated with hemodialysis or peritoneal dialysis in Tunisia. For this launch Médis expands its product portfolio after biosimilar enoxaparin and unfractionated heparin.

Biosimilars are biological products " similar" to the reference pharmaceutical products (originator products). Thanks to their lower cost, biosimilar medicines improve access to health care while offering patients a degree of efficiency and safety profile similar to that of the originator products.